The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

The Garvan team revealed that this is not the case—rather, the critical trigger is mutations in "rogue clone" B cells. "This discovery fundamentally changes our understanding of how infections ...

Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a ...

GenScript’s sophisticated, proprietary rabbit mAb discovery technology involves the isolation and cloning of rabbit B cells, and it capitalizes on the rabbit’s innate capability to produce ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

The Beacon ® optofluidic platform maintains the diversity of B cells, producing high-quality positive hits at an early discovery stage, and preventing "good clones" from being lost. The Beacon ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

So, here's why you'll probably never have to fight your evil clone. This is Dolly. Just kidding, that's a regular sheep. This is Dolly, the first mammal cloned successfully from an adult cell.